China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced revisions to its private placement plan, downsizing the initially disclosed proceeds from RMB 2.608 billion (USD 360 million) in April to RMB 1.848 billion (USD 255.1 million). The adjusted funds will be allocated towards new drug research and development, a global-aligned novel drug industrialization program, and supplementary working capital.
Allocation of Reduced Proceeds
The company’s decision to reduce the private placement proceeds reflects a strategic reallocation of resources. The revised amount will now be directed towards:
- New drug research and development: This will include the advancement of innovative pharmaceutical products through various stages of research and development.
- Global-aligned novel drug industrialization program: This initiative aims to align with international standards and practices in the production and commercialization of novel drugs.
- Supplementary working capital: The funds will also be used to bolster the company’s operational liquidity and financial stability.
Implications for Dizal Pharmaceutical
The revision of the private placement plan comes as Dizal Pharmaceutical continues to focus on expanding its pipeline and enhancing its capabilities in drug development and industrialization. The company remains committed to meeting the demands of the global pharmaceutical market while ensuring financial prudence in its capital raising efforts.-Fineline Info & Tech
Leave a Reply